McLaughlin Kylie A, Nemeth Zsuzsanna, Bradley Conor A, Humphreys Luke, Stasik Izabela, Fenning Catherine, Majkut Joanna, Higgins Catherine, Crawford Nyree, Holohan Caitriona, Johnston Patrick G, Harrison Timothy, Hanna Gerard G, Butterworth Karl T, Prise Kevin M, Longley Daniel B
Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK.
Mol Cancer Ther. 2016 Oct;15(10):2432-2441. doi: 10.1158/1535-7163.MCT-16-0211. Epub 2016 Jul 29.
Resistance to radiotherapy due to insufficient cancer cell death is a significant cause of treatment failure in non-small cell lung cancer (NSCLC). The endogenous caspase-8 inhibitor FLIP is a critical regulator of cell death that is frequently overexpressed in NSCLC and is an established inhibitor of apoptotic cell death induced via the extrinsic death receptor pathway. Apoptosis induced by ionizing radiation (IR) has been considered to be mediated predominantly via the intrinsic apoptotic pathway; however, we found that IR-induced apoptosis was significantly attenuated in NSCLC cells when caspase-8 was depleted using RNA interference (RNAi), suggesting involvement of the extrinsic apoptosis pathway. Moreover, overexpression of wild-type FLIP, but not a mutant form that cannot bind the critical death receptor adaptor protein FADD, also attenuated IR-induced apoptosis, confirming the importance of the extrinsic apoptotic pathway as a determinant of response to IR in NSCLC. Importantly, when FLIP protein levels were downregulated by RNAi, IR-induced cell death was significantly enhanced. The clinically relevant histone deacetylase (HDAC) inhibitors vorinostat and entinostat were subsequently found to sensitize a subset of NSCLC cell lines to IR in a manner that was dependent on their ability to suppress FLIP expression and promote activation of caspase-8. Entinostat also enhanced the antitumor activity of IR in vivo Therefore, FLIP downregulation induced by HDAC inhibitors is a potential clinical strategy to radiosensitize NSCLC and thereby improve response to radiotherapy. Overall, this study provides the first evidence that pharmacological inhibition of FLIP may improve response of NCSLC to IR. Mol Cancer Ther; 15(10); 2432-41. ©2016 AACR.
癌细胞死亡不足导致的放疗抵抗是非小细胞肺癌(NSCLC)治疗失败的重要原因。内源性半胱天冬酶 - 8抑制剂FLIP是细胞死亡的关键调节因子,在NSCLC中经常过表达,并且是通过外源性死亡受体途径诱导的凋亡细胞死亡的既定抑制剂。电离辐射(IR)诱导的凋亡一直被认为主要通过内源性凋亡途径介导;然而,我们发现当使用RNA干扰(RNAi)耗尽半胱天冬酶 - 8时,NSCLC细胞中IR诱导的凋亡明显减弱,这表明外源性凋亡途径参与其中。此外,野生型FLIP的过表达,而不是不能结合关键死亡受体衔接蛋白FADD的突变形式,也减弱了IR诱导的凋亡,证实了外源性凋亡途径作为NSCLC中对IR反应的决定因素的重要性。重要的是,当通过RNAi下调FLIP蛋白水平时,IR诱导的细胞死亡明显增强。随后发现临床相关的组蛋白脱乙酰酶(HDAC)抑制剂伏立诺他和恩替诺特以依赖于它们抑制FLIP表达和促进半胱天冬酶 - 8激活的能力的方式使一部分NSCLC细胞系对IR敏感。恩替诺特在体内也增强了IR的抗肿瘤活性。因此,HDAC抑制剂诱导的FLIP下调是使NSCLC对放疗增敏从而改善放疗反应的潜在临床策略。总体而言,本研究提供了首个证据,即FLIP的药理学抑制可能改善NCSLC对IR的反应。《分子癌症治疗》;15(10);2432 - 41。©2016美国癌症研究协会。